The purpose of this study was to identify the early predictor of survival for prostate cancer patients with bone metastasis. We reviewed 87 prostate cancer patients with bone metastasis who had received primary androgen deprivation therapy (PADT) at our institution. The medical records of the patients were examined with respect to laboratory data, pathological results, PSA response to PADT and clinical outcome. The overall survival (OS) rates were analyzed with reference to the nadir PSA level and time to PSA nadir (TTN) following PADT by Kaplan-Meier method. In all, 59 patients (67%) had progression to castration-resistant prostate cancer. Nadir PSA o0.2 ng ml -1 (lower PSA nadir) during PADT were observed in 47 patients (54%). Multivariate analysis revealed that the extent of disease on bone scan (P ¼ 0.04), lower PSA nadir following PADT (P ¼ 0.003), albumin (P ¼ 0.04) and lactate dehydrogenase (P ¼ 0.01) were independent prognostic factors for survival. OS rates in the patients with lower PSA nadir were significantly higher. Longer TTN (49 months) identified patients with prolonged OS in both lower and higher PSA nadir groups. PSA nadir o0.2 ng ml -1 and prolonged TTN (49 months) following PADT might be the most important early predictors for longer survival in prostate cancer patients with bone metastasis.
Introduction
Patients with advanced stage prostate cancer initially respond well to hormone therapy, but then progress to castration-resistant prostate cancer, which is accompanied with high mortality rate. 1 Several clinical and laboratory data have been proposed as prognostic factors that correlate with the clinical response to hormone therapy, including performance status, extent of bone metastases, serum alkaline phosphatases, hemoglobin and testosterone levels. 2, 3 However these prognostic parameters, mostly clinical, poorly correlate with the clinical outcome. Thus, there is an urgent need for new tools that can predict progression and survival at the time of diagnosis. The J-CAPRA score is a novel, validated score for predicting outcomes among patients undergoing primary androgen deprivation therapy (PADT) across the full spectrum of risk and stage, including advanced disease. 4 Nadir PSA level after hormone therapy has been reported as an important tool to predict progression-free survival in patients with metastatic prostate cancer. [5] [6] [7] However, it is not clear if the same risk factors are equally predictive of biochemical recurrence in patients with or without bone metastasis at presentation. 3, 8, 9 Therefore, we focused on prostate cancer patients with bone metastasis (M1b prostate cancer patients) to investigate the value of these factors to predict prognosis.
The ability to predict which patients are more likely to develop early castration-resistant disease could be helpful when choosing the best treatment strategy. For this purpose, we analyzed several biochemical and clinicopathological variables that might influence the castration-resistant disease and the poor overall survival (OS) in prostate cancer patients with bone metastasis.
Materials and methods
A retrospective study was conducted in 87 patients with M1b prostate cancer (UICC TNM classification, 6th edn, 2002) at a time of diagnosis from January 2000 to December 2009. Bone metastases were confirmed by bone scan before PADT. All patients received PADT with luteinizing hormone-releasing hormone agonist or surgical castration accompanied with an antiandrogen (combined androgen blockade), and were followed at our hospital every 4 weeks. The antiandrogens, flutamide or bicartamide were used initially. The extent of bone metastases (extent of disease on bone scan (EOD) grade) was graded as M1 (fewer than six hot spots), M2 (between 6 and 20 hot spots), M3 (420 hot spots) or M4 (superscan pattern or 475% involvement of skeleton) according to Soloway's classification. 10 PSA was serially measured every 4 weeks during PADT treatment. PADT failure was determined by exponentially increasing PSA at three time points, which were measured every 4 weeks interval, (the date correspond to the day that the increase was first observed). 11 After PADT failure, the following treatments were serially performed: first, check for antiandrogen withdrawal syndrome; second, the second-line antiandrogen treatment with other antiandrogens; third, estramustine phosphate (daily dose of 560 mg); fourth, dexamethason (daily dose of 0.5-1.5 mg) and fifth, chemotherapy with docetaxel (70 mg m -2 tri-weekly). Post docetaxel failure, no further treatment, such as cabazitaxel and sipuleucel-T were used, since they have not been approved in Japan. As docetaxel has been approved for its use in Japan in 2008, only nine patients were treated with docetaxel after the dexamethason failure, The OS rate, which was defined as the time when PADT was initiated to the date of death from any causes, was analyzed in terms of the nadir PSA (the lowest PSA level during PADT) and time to nadir (TTN). TTN was defined as the duration time from the initiation of PADT to the date that the lowest PSA value was first recorded. 12 To evaluate the relationship between clinicopathological factors and the nadir PSA level, w 2 and MannWhitney U-tests were used. To determine the significant factors in predicting patient's prognosis, multivariate analysis was performed according to the Cox proportional hazards regression model. Only the variables found to be significant on univariate analysis (Po0.05) were entered into the multivariate analysis. OS was calculated with the Kaplan-Meier method. Significance was determined by log-rank test. Bonferroni correction was used in pairwise comparison with keep the overall significance level of 0.05 in Figure 3 . The statistical analysis was undertaken using SAS software, version 8.2 (SAS Institute, Cary, NC, USA) and Po0.05 was considered to be statistically significant.
An institutional review board of our hospital approved this study.
Results
Clinical characteristics of the patients in this study are shown in Table 1 . Median age was 74 years (57-89), and median follow-up was 37.8 months (range 1-116). In all, 59 patients (67%) had progression to PADT failure. As the median PSA nadir was 0.2 ng ml -1 , we selected as an optimal threshold value (range 0.008-1310). Pre-PADT PSA was dichotomized to o500 and X500 ng ml -1 in this study according to J-CaPRA score. 4 The univariate analysis showed that performance status, EOD, T-classification, hemoglobin, albumin, lactate dehydrogenase, initial PSA and nadir PSA o0.2 ng ml -1 affected OS (Table 2) . By multivariate analysis, significant independent risk factors that affected OS were EOD grade (P ¼ 0.04), albumin (P ¼ 0.04), lactate dehydrogenase (P ¼ 0.01) and nadir PSA o0.2 ng ml PSA nadir and time to nadir are prognostic factors for prostate cancer patients T Sasaki et al initial PSA (P ¼ 0.005), initial hemoglobin levels (P ¼ 0.001), initial albumin level (P ¼ 0.02), T-classification (Po0.001), lactate dehydrogenase (Po0.001), performance status (P ¼ 0.005) and with PADT failure (Po0.001). Gleason score, existence of non-bone metastasis did not differ significantly between two groups (Table 4) . PADT failure was seen in 24 patients (51.0%) with PSA nadir p0.2 and 35 patients (87.5%) in nadir 40.2. In our series, median TTN was 9 months. We therefore investigated the differences of OS in different TTN thresholds (o6 M, 6-12 M and 412 M). A reduced risk of OS was observed as TTN increased (Figure 2) . A Kaplan-Meier plot of OS by PSA nadir and TTN showed that significant differences were seen in OS between TTN p9 months and TTN 49 months in both nadir p0.2 and nadir 40.2 groups (P ¼ 0.01, and Po0.001, respectively). Lower PSA nadir levels (PSA p0.2) correlated with increased OS in patients with TTN p9 months (Po0.001), whereas nadir PSA levels (p0.2 vs 40.2) had no significant difference with OS in patients with TTN 49 months (Figure 3 ).
Discussion
Prognosis of the M1b prostate cancer is very poor, and it has been reported that the median survival after castration-resistant disease is 40 months for patients initially staged with M1b. 13 Our aim was to find more reliable early prognostic factors in M1b prostate cancer before or during initial hormone therapy. We believe it Overall survival Figure 1 Comparison of the overall survival between patients with PSA nadir o0.2 ng ml -1 (solid line) and 40.2 ng ml -1 (dotted line) following primary androgen deprivation therapy (log rank test: Po0.001). PSA nadir and time to nadir are prognostic factors for prostate cancer patients T Sasaki et al could be useful for decision making of the best treatment strategy to predict which patients are more likely to develop early castration-resistant disease related to survival. Many prognostic factors for advanced prostate cancer have been evaluated, with initial hemoglobin, erythrocyte sedimentation rate, serum albumin, alkaline phosphatase, lactate dehydrogenase, performance status and body weight generally regarded as the prognostic factors for survival after PSA relapse of patients with advanced prostate cancer.
14-17 Some of these factors might not predict accurate cancer-specific survival, because some of these correlate not only with cancer characteristics but also patient's conditions, such as weakness, malnutrition and complications. General conditions of most patients in our study were not poor, the number of patients with initial albumin levels o3.0 mg dl -1 were only 4 (4.5%), and performance status 42 were only 4 (4.5%), respectively. Therefore, our study demonstrates more accurately that EOD grade and nadir PSA o0.2 ng ml -1 following PADT are independent prognostic factors for survival for M1b prostate cancer patients.
Although measurement of PSA levels is useful for evaluating the effects of hormone therapy in patients with advanced prostate cancer, there is disagreement on the prognostic importance of various PSA indexes after treatment, such as PSA level at initial diagnosis, pattern of PSA decrease after hormone therapy, half-life of PSA, nadir PSA level after treatment, TTN and percentage of PSA decrease. Furthermore, there have been few studies on whether these PSA indexes accurately predict the progression to castration-resistant prostate cancer. 7 Among PSA indexes, PSA nadir and TTN have been recently reported as good predictors of androgenindependent progression 7, 18 and survival 12, 14, 19 of metastatic prostate cancer. However, there is no consensus of both optimal threshold of PSA nadir and cut-off value of TTN after PADT for predicting survival. Kwak et al. reported a lower limit for the nadir PSA level of 1.1 ng ml -1 gives optimal sensitivity and specificity. Morote et al. 18 reported that a PSA nadir of o2 ng ml -1 was associated with a low risk of PSA progression. As for survival, Hussain et al. 19 reported that a PSA of 4 ng ml -1 or less after 7 months of androgen deprivation is a strong and specific predictor for risk of death. Tomioka et al.
14
reported that the patients with nadir PSA o2 ng ml -1 showed the longest survival. Furthermore, Choueiri et al. 12 have recently reported that PSA nadir o0.2 ng ml -1 and a TTN of 46 months were optimal predictor for a longer OS in patients with metastatic disease.
Hori et al. 20 have reported that key-independent factors predicting biochemical relapse were high PSA nadir and shorter TTN, and a nadir of o1 ng ml -1 and TTN of 412 months specifically identified M1b prostate cancer patients with reduced risks of biochemical relapse from PADT. Our multivariate analysis also showed that nadir PSA o0.2 ng ml -1 following PADT is an independent prognostic factors for survival for M1b prostate cancer patients. OS rates were significantly higher in patients with nadir PSA o0.2 ng ml -1 . The variability for optimal PSA nadir might be due to differences in patient's background including stage, race and so on. The difference of endpoints (progression-free survival or OS) could also affect the optimal PSA nadir. Although we did not investigate lower thresholds o0.2 ng ml -1 because of low number of cases, lower nadir PSA could be associated with reduced risk of PSA progression and OS.
It is generally considered that rapid reduction of PSA would correlate with more prostate cancer cell death followed by higher survival, and shorter TTN correlated with longer remission periods. 21 Whereas, together with the literatures 12, 20 and this study, it is shown that longer TTN is also associated with longer survival. Furthermore, Chouieri et al. 12 reported that the association between TTN and survival was limited only to patients with a PSA nadir 40.2 ng ml -1 , and a rapid PSA decline also associated with a shorter OS, although only 32.4% of M1b patients were included in their study. Our data suggested that longer TTN might be associated with increased survival even in the patients with PSA nadir o0.2 ng ml -1 . The difference might be due to the different patient population. Thus, both our results and the data from the studies reported by Choueiri et al. and Hori et al. 12, 20 suggest that a rapid response to androgen deprivation therapy indicates more aggressive disease. The possible explanation is that, castration-resistant prostate cancer cells, which are PSA-producing, can Overall survival Figure 3 Overall survival according to the PSA nadir and the time to PSA nadir (TTN).
PSA nadir and time to nadir are prognostic factors for prostate cancer patients T Sasaki et al grow in low androgen environment, and would be present in a large number with heterogeneous prostate cancer in bone metastases. A prostate cancer cell line that displays these characteristics (PSA-producing and androgen independent) is available for experimental research. 22, 23 The rapid reduction of PSA simply may be affected by downregulation of PSA expression, which is regulated by androgen through androgen receptor, rather than prostate cancer cell death. Furthermore, PSA reduction by androgen deprivation might be faster in these cells than in androgen-dependent prostate cancer cells. Another possibility is that an adequate environment for growing hormone-resistant prostate cancer cells might be induced by a rapid removal of hormonesensitive prostate cancer cells.
We recognize the limitations of a retrospective study that includes a relatively few cases. However, we believe that further prospective studies with large cohort size are required to confirm our initial findings these findings.
In conclusion, PSA nadir o0.2 ng ml -1 and longer TTN (49 months) during initial hormone therapy (combined androgen blockade) are the most important early predictors for survival in prostate cancer patients with bone metastasis. Both of them may predict the response to androgen deprivation therapy, and could be helpful for decision making of treatment strategy, for example, early use of docetaxel chemotherapy, for prostate cancer patients with bone metastasis.
